GlassScriptPhysician profile
Wingnay Ng Chernesky
NPI 1437830619
$4,661.03
in general payments reported to CMS, 2019-2025
36 companies · $2,469 in 2025
The $2,469 reported for 2025 was more than what 95% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $697 · 2024: $1,495 · 2025: $2,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,577 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,577.03 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $506.34 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $377.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $367.18 | 2024-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $355.06 | 2024-2025 | |
| Ardelyx, INC. | $354.19 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $324.66 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.16 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $209.18 | 2023-2025 | Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $182.27 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $180.50 | 2024-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $150.54 | 2024-2025 | |
| Lilly USA, LLC | $148.77 | 2023-2025 | Omvoh, Trulicity, Mounjaro |
| Gilead Sciences, INC. | $146.93 | 2024 | |
| Qol Medical, LLC | $127.10 | 2024-2025 | Sucraid, Sucraid |
| Pfizer INC. | $116.11 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $91.14 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Ipsen Biopharmaceuticals, INC | $76.42 | 2024-2025 | Iqirvo |
| Glaxosmithkline, LLC. | $73.64 | 2023-2024 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $66.70 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $60.28 | 2024-2025 | Dupixent |
| Corcept Therapeutics | $59.12 | 2023-2024 | Korlym |
| Celltrion USA INC. | $57.80 | 2025 | Vegzelma |
| Myriad Women'S Health, INC. | $42.11 | 2023 | Myrisk |
| Phathom Pharmaceuticals, INC. | $39.82 | 2024-2025 | Voquezna |
| Amgen INC. | $38.56 | 2024-2025 | Uplizna, Otezla, Repatha |
| Mallinckrodt Hospital Products INC. | $35.89 | 2024 | Terlivaz |
| Exact Sciences Corporation | $34.37 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $31.92 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.73 | 2023 | Jardiance, Synjardy |
| Grifols USA, LLC | $24.45 | 2023 | Prolastin-C Liquid |
| Dexcom, INC. | $20.30 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.60 | 2024 | Caplyta |
| Pharmacosmos Therapeutics INC. | $17.47 | 2025 | Monoferric |
| Alnylam Pharmaceuticals INC. | $16.89 | 2025 | Givlaari |
| E.R. Squibb & Sons, L.L.C. | $16.37 | 2023 | Camzyos |
| Esperion Therapeutics, INC. | $12.70 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wingnay Chernesky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.